Novartis' Ultibro® Breezhaler® improved lung function and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Novartis' Ultibro® Breezhaler® improved lung function and COPD symptoms after direct switch from previous treatment
  • Ultibro ® Breezhaler ® improved lung function and breathlessness after direct switch from long-acting bronchodilators or steroid-containing combination therapies  
  • Results further support the 2017 GOLD recommendations that dual bronchodilation should be the foundation treatment for the majority of symptomatic COPD patients  
  • Data from the pragmatic CRYSTAL study showcased for the first time at the 2016 British Thoracic Society Winter Meeting in London, UK

Basel, December 8, 2016 - Novartis today announced positive results from the first large-scale study exploring the effects of directly switching symptomatic, non-frequently exacerbating patients with moderate COPD from their current treatments, including steroid-containing combinations and long-acting bronchodilators, to the dual bronchodilator Ultibro ® Breezhaler ® (indacaterol/glycopyrronium) 110/50 mcg.

In the CRYSTAL study, patients with moderate COPD who were switched to Ultibro Breezhaler from their previous therapy (LABA+ICS * or LABA or LAMA***) experienced superior improvements in lung function (trough FEV 1 ) and breathlessness**** at week 12 (p<0.0001). Significantly, CRYSTAL is the first LABA/LAMA pragmatic trial, designed to mimic clinical practice, so treatment switching occurred without a washout period[1].

"Today's results are significant as they show for the first time the positive effect of directly switching to Ultibro Breezhaler from other COPD treatments, such as inhaled steroid-containing combination therapies," said Vasant Narasimhan, Global Head Drug Development and Chief Medical Officer for Novartis. "By showing that improved symptom control can be achieved through using Ultibro Breezhaler, the CRYSTAL study provides further support to limit the use of inhaled steroid-containing therapies to specific patient types that really need it."

Ultibro Breezhaler was also well tolerated in the CRYSTAL study[1].

About CRYSTAL CRYSTAL was a prospective, multicenter, 12-week, randomized, pragmatic, open-label trial. Patients were recruited into four groups according to previous medication and symptoms, and randomized to a direct switch to Seebri ® Breezhaler ® (glycopyrronium) 50 mcg or Ultibro ® Breezhaler ® (indacaterol/glycopyrronium)110/50 mcg once daily vs. continuation of previous treatment. The study enrolled a total of 4,389 symptomatic, non-frequently exacerbating (up to one exacerbation in the previous year) patients with moderate COPD and 2,159 patients received Ultibro Breezhaler or continued their baseline therapy. The Seebri Breezhaler treatment arms of the study were underpowered due to sample size.

Co-primary objectives of the study were:

  • Superiority of Ultibro Breezhaler vs. LABA, LAMA and LABA+ICS in terms of improvement of lung function (trough FEV 1 ) and breathlessness (transition dyspnoea index) at week 12.
  • Superiority of Seebri Breezhaler  vs. previous SABA and/or SAMA § treatment in terms of improvement of lung function (trough FEV 1 ) and breathlessness (transition dyspnoea index) at week 12
  • Non-inferiority of Seebri Breezhaler  vs. previous LABA or LAMA treatment in terms of improvement of lung function (trough FEV 1 ) and breathlessness (transition dyspnoea index) at week 12.

              About Ultibro Breezhaler Ultibro Breezhaler (indacaterol/glycopyrronium) 110/50 mcg is a once-daily LABA/LAMA dual bronchodilator approved in the European Union (EU) as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD[2]. Clinical trials have shown that it offers statistically significant improvements in bronchodilation compared to treatments widely used as current standards of care, including SFC 50/500 mcg[3]-[5] and open-label tiotropium (18 mcg). Ultibro Breezhaler is also currently the only steroid-free treatment to offer prescribers clinically proven superiority over the most prescribed ICS/LABA combination ** in preventing COPD exacerbations[6]. Ultibro Breezhaler is currently approved for use in over 90 countries worldwide, including countries within the EU and Latin America, Japan, Canada, Switzerland and Australia.

About Seebri Breezhaler Seebri Breezhaler (glycopyrronium) 50 mcg is a once-daily LAMA bronchodilator approved in the European Union (EU) as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD[7]. Seebri Breezhaler is approved for use in over 90 countries, including countries within the EU and Latin America, Japan, Canada, Switzerland and Australia.

Glycopyrronium and certain use and formulation intellectual property were exclusively licensed to Novartis in April 2005 by Sosei and Vectura.

About the Novartis COPD portfolio Novartis is committed to addressing the unmet medical needs of COPD patients and improving their quality of life by providing innovative medicines and devices. The Novartis COPD portfolio includes Ultibro Breezhaler (indacaterol/glycopyrronium), Seebri Breezhaler (glycopyrronium) and Onbrez ® Breezhaler ® /Arcapta ® Neohaler ® (indacaterol), which are all indicated as maintenance treatments for COPD patients.

Novartis continues development of respiratory products for delivery via the low resistance Breezhaler ® inhalation device, which makes it suitable for patients with different severities of airflow limitation[8]. The Breezhaler device allows patients to hear, feel and see that they have taken the full dose correctly[2],[8].

About COPD Chronic obstructive pulmonary disease (COPD) affects an estimated 210 million people worldwide[9] and is the third leading cause of death[10]. It is progressive (usually gets worse over time), and can be a life-threatening disease[9],[11]. COPD makes it difficult to breathe, with symptoms that have a destructive impact on patients' function (i.e. activity limitation, decreased mobility) and quality of life[9],[11].

Disclaimer The foregoing release contains forward-looking statements that can be identified by words such as "support," "recommendations," "should," "can," "committed," "continues," or similar terms, or by express or implied discussions regarding potential new indications or labeling for Ultibro Breezhaler and the other products in the Novartis COPD portfolio, or regarding potential future revenues from Ultibro Breezhaler and the other products in the Novartis COPD portfolio. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Ultibro Breezhaler or the other products in the Novartis COPD portfolio  will be submitted or approved for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that Ultibro Breezhaler or the other products in the Novartis COPD portfolio will be commercially successful in the future. In particular, management's expectations regarding Ultibro Breezhaler and the other products in the Novartis COPD portfolio could be affected by, among other things, the uncertainties inherent in research and development, including unexpected clinical trial results and additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain proprietary intellectual property protection; general economic and industry conditions; global trends toward health care cost containment, including ongoing pricing pressures; unexpected safety, quality or manufacturing issues, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are available in approximately 180 countries around the world. For more information, please visit http://www.novartis.com .

Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis For Novartis multimedia content, please visit www.novartis.com/news/media-library For questions about the site or required registration, please contact media.relations@novartis.com

Notes * Long-acting beta 2 -adrenergic agonist + inhaled corticosteroid (free or fixed-dose combinations) *** Long-acting muscarinic antagonist **** Transition dyspnea index (TDI) § Short-acting beta agonist and/or short-acting muscarinic antagonist ** Seretide ® Accuhaler ® (salmeterol/fluticasone) 50 microgram /500 microgram /dose inhalation powder. Seretide and Accuhaler are registered trademarks of the GlaxoSmithKline group of companies

References [1] Vogelmeier C, Aalamian-Mattheis M, Greulich T, et al . Efficacy and safety of the direct switch from various previous treatments to glycopyrronium or indacaterol/glycopyrronium in patients with moderate COPD: The CRYSTAL Study. Abstract presented at the British Thoracic Society Winter Meeting: 6 December 2016 [2] Ultibro Breezhaler EU Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_...151255.pdf [Accessed 21 November 2016]. [3] Vogelmeier C, et al . Once-daily QVA149 provides clinically meaningful improvements in lung function and clinical outcomes versus placebo, indacaterol, glycopyrronium, tiotropium and salmeterol/fluticasone in patients with COPD. [ATS abstract 40759; Session C45; Date: May 21, 2013 Time: 8:15 -10:45].  [4] Vogelmeier C, et al. Once-daily QVA149 provides clinically meaningful improvements in lung function and clinical outcomes. [ERS 2013 abstract 851178; Session 82; Date: September 8, 2013 Time: 12:50-14:40]. [5] Banerji D, et al . Dual bronchodilation with once-daily QVA149 improves dyspnea and health status and reduces symptoms and rescue medication use in patients with COPD: the IGNITE trials. [ERS 2013 abstract 851388; Session 346; Date: September 10, 2013 Time: 8:30-10:30]. [6] Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. New England Journal of Medicine. 2016. Available at: www.nejm.org/doi/full/10.1056/NEJMoa1516385 [Accessed 21 November 2016]. [7] Seebri Breezhaler EU Summary of Product Characteristics. [Online] Revised 19-Oct-2016. Available at: http://www.medicines.org.uk/emc/medicine/2713...Inhalation +Powder,+Hard+Capsules+44mcg/ [Accessed 21 November 2016]. [8] Pavkov R, Mueller S, Fiebich K, et al. Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol. CMRO. 2010;26; 11:2527-2533. [9] Global Alliance Against Chronic Respiratory Diseases (GARD). Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach. Available at: http://www.who.int/gard/publications/GARD_Manual/en/ [Accessed 21 November 2016]. [10] World Health Organization: The top 10 causes of death fact sheet N o 310. Available at: http://www.who.int/mediacentre/factsheets/fs310/en/ [Accessed 21 November 2016]. [11] Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2016. Available at: http://goldcopd.org/ [Accessed 21 November 2016].

# # #

Novartis Media Relations Central media line: +41 61 324 2200 E-mail: media.relations@novartis.com

Eric Althoff Novartis Global Media Relations +41 61 324 7999 (direct) +41 79 593 4202 (mobile) eric.althoff@novartis.com Claudia Paproth Novartis Pharma Communications +41 61 696 5556 (direct) +41 79 560 4713 (mobile) claudia.paproth@novartis.com  

Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: mailto:investor.relations@novartis.com

Central   North America  
Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448
Pierre-Michel Bringer +41 61 324 1065 Sloan Pavsner +1 212 830 2417
Thomas Hungerbuehler +41 61 324 8425    
Isabella Zinck +41 61 324 7188    
Attachments:

http://www.globenewswire.com/NewsRoom/Attachm...674e37533d

Scroll down for more posts ▼

Top 10 Most Recent News Articles

1095 Days Finds the Army's Long, Ordinary War Life

Updated Category News Views 125

A cracked barracks window can explain more than a polished battlefield legend. Dean R. Cherry's 1095 Days: Three Years in the Green Machine, newly released by Palmetto Publishing, puts its weight on the parts of Army life that war stories often shove into the background: cold, waiting, paperwork, arbitrary rules, lousy living conditions, and the private mental math of...

Continue Reading
Evotec’s Second IND Adds Proof to Its Glue Platform

Updated Category News Views 73

Two IND acceptances from one long-running alliance is not nothing, especially in a drug-discovery business where plenty of polished platform talk never makes it to the clinic. Evotec has cleared that modest but meaningful bar again with Bristol Myers Squibb: a second molecular-glue candidate has received FDA acceptance for an Investigational New Drug application. The...

Continue Reading
Dimora's MegaSorb Review Sharpens Wound Care Choices

Updated Category News Views 105

Wound care is one of those corners of healthcare where flashy language runs into real-life consequences fast. Dimora Medical’s newly announced collaboration with podiatric physician Dr. Ebonie Vincent-Sleet brings a professional voice to its MegaSorb silicone foam dressing line, specifically a 4×4-inch product reviewed for its intended place in care. That is useful...

Continue Reading
Common Tiger Bets $499 on Better Outdoor Seating Design

Updated Category News Views 59

A chair that refuses to slump into the camping aisle is Common Tiger's whole argument, and frankly it is a smarter argument than another flimsy fold-up contraption pretending comfort is optional. The Los Angeles, female-founded and women-owned brand is launching with one product, The Daymaker, after four years of development. That is a long runway for a debut chair, which...

Continue Reading
Somerville’s New Immersive Bet Has Room to Grow Locally

Updated Category News Views 167

A passcard, a hidden door, and 12,000 square feet of mischief have landed at Somernova. Edge of Elsewhere, the new flagship attraction from Boston-area creative studio Midnight Mansion, is open in Somerville’s Union Square as of November 18, 2026. It is part interactive art installation, part puzzle game, part physical story world. That sounds delightfully odd, which is...

Continue Reading
Neusoft's OneCoreGo Win Puts Auto Software in Focus

Updated Category News Views 60

A Dashboard Award Is Not Just About Pretty Pixels Crystal-like graphics and augmented-reality pathways may sound like the sort of thing a marketing department dreams up after too much coffee, but the more interesting bit in Neusoft's latest news is the machinery underneath. OneCoreGo 7.0 has received the Red Dot Design Award after taking a German iF Design Award earlier...

Continue Reading
MegaRobo's Nearly $200 Million Bet on Learning Labs

Updated Category News Views 98

A lab robot that merely follows instructions is old news; a system that learns from the mess it makes is the expensive part. MegaRobo has raised nearly US$200 million to push toward that harder prize: infrastructure that links AI reasoning to actual experiments, instruments, automation and the results that come back. For investors watching AI for Science, this is more...

Continue Reading
Innoviz's 1-for-20 Split Is a Listing Lifeline Test

Updated Category News Views 112

A twenty-share pile of INVZ is about to become one share, and nobody should confuse that paperwork with a turnaround. Innoviz plans to enact a 1-for-20 reverse split at 11:59 p.m. Eastern on Friday, December 4, with split-adjusted trading expected when Nasdaq opens on December 7. This is a blunt instrument aimed at one immediate problem: getting the quoted share price...

Continue Reading
Dar Global’s $700M Qatar Bet Leans on Trump Branding

Updated Category News Views 7

Luxury property launches rarely arrive quietly, and this one came wrapped in Palm Beach ceremony, championship golf and a very loud brand name. Dar Global has formally introduced Trump International Simaisma, Qatar, a QAR 2.5 billion development—about $700 million—alongside The Trump Organization. That is a meaningful chunk of real estate ambition, not a little side...

Continue Reading
EmTech AI 2027 Puts AI Ambitions Through Reality Test

Updated Category News Views 5

A three-day gathering cannot settle AI's biggest arguments, but MIT Technology Review has picked the right fight for EmTech AI 2027: make the industry face a Reality Test. The conference runs May 11–13, 2027, at MIT's campus and online, and that theme lands because the AI conversation has spent plenty of time admiring the engine while skipping the ugly maintenance bill....

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Partnership Between ShengShu Technology and Lenovo

Updated Category News Views 235

ShengShu Technology and Lenovo Forge a Creative Alliance ShengShu Technology, known for its groundbreaking advancements in the realm of generative artificial intelligence, has announced a strategic partnership with Lenovo. This collaboration aims to integrate Vidu, their flagship generative video solution, into Lenovo PCs, creating a powerful tool for content creators...

Continue Reading
Stora Enso's Strategic Review Aims to Boost Forest Asset Value

Updated Category News Views 292

Stora Enso Embarks on a Strategic Review of Forest Assets STORA ENSO OYJ announces a strategic review focusing on its Swedish forest assets, intending to enhance the company's operational efficiency. This initiative stems from Stora Enso's commitment to renewable packaging, aiming to streamline its operations while simultaneously maximizing shareholder value. Exploring...

Continue Reading
KuCoin's Innovative Journey: Building Trust in Crypto Industry

Updated Category News Views 145

KuCoin's Strategic Transformation in 2025 KuCoin proudly announced the release of its Annual Review, reflecting on a pivotal year characterized by commitment to compliance, security, and sustainable practices. This annual report, titled A Renewed Brand. A Year Built on Trust., reflects the company's dedication to evolving its platform in accordance with regulatory...

Continue Reading
Global Markets Navigate Uncertainty in Early 2025

Updated Category News Views 211

A Global Perspective as 2025 Begins As the world welcomed 2025, an atmosphere of caution enveloped the markets. Investors are on edge, particularly with the anticipation surrounding the return of a certain political figure to the White House. The policies proposed, specifically hefty import tariffs, tax cuts, and immigration restrictions, have significantly shaped market...

Continue Reading
Earnings Outlook for Datavault AI Inc. - What Investors Should Know

Updated Category News Views 224

Datavault AI Inc.: Understanding the Earnings Forecast Datavault AI Inc. - Common Stock (NASDAQ: DVLT) is gearing up for the announcement of its quarterly earnings report. Investors are keenly awaited for fresh insights as expectations ramp up for this tech-focused company. Projected Earnings and Market Sentiment Analysts are predicting that Datavault AI Inc. will report...

Continue Reading